Updates are available Correction dated 2021-06-25
Click to view Correction: https://doi.org/10.1186/s40478-021-01210-w
-
Authors
Lian, Xiaolei
Kats, Dina
Rasmussen, Samuel
Martin, Leah R.
Karki, Anju
Keller, Charles
Berlow, Noah E. https://orcid.org/0000-0001-8666-3152
-
Funding
Funding for this research was provided by:
Matthew Larson Foundation for Pediatric Brain Tumors
- License Information
-
More Information
Article History
Received: 10 February 2021
Accepted: 18 April 2021
First Online: 17 May 2021
Change Date: 25 June 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s40478-021-01210-w
Declarations
:
: Not applicable.
: Not applicable.
: Author CK is a co-founder of Artisan Biopharma, a wholly-owned public benefit corporation of the Children’s Cancer Therapy Development Institute (cc-TDI). CK through cc-TDI also has research frameworks or collaborations with Roche Genentech, Eli Lilly, and Novartis. The chorioallantoic membrane (CAM) assay process is being developed for patenting and commercialization by authors CK and SR. The remaining authors declare no competing interests.
